Percentage of patients achieving ≥4-point reduction in Peak Pruritus NRS
Improvement seen as early as WEEK 2
(≈9% vs ≈3%; P=0.0097)
In 3 pivotal trials, adult patients with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT 300 mg Q2W or placebo. In Trial 3, concomitant TCS was used. An endpoint included the reduction in itch from baseline to Week 16 (all trials) and 52 (Trial 3), as defined by ≥4-point improvement in the Peak Pruritus numerical rating scale (NRS).1
Adult patients experienced a ≥4-point reduction in itch after the first dose as measured at Week 2 (≈9% vs ≈3%)1,2
Sustained itch reduction (Peak Pruritus NRS) at 1 year with DUPIXENT + TCS in Trial 3 (secondary endpoint)2,4,a-c
Trial 3: Concomitant Therapy With TCS
Long-term itch reduction up to 52 weeks2
In a post hoc analysis of 3 pooled trials in adults
DUPIXENT monotherapy and DUPIXENT + TCS demonstrated consistent itch reduction across all tested racial groups vs placebo and placebo + TCS (black/African American, Asian, and white)5
A patient-reported measure that uses a 0- to 10-point scale, with which patients are asked6:
"On a scale of 0 to 10, how would you rate your itch overall (on average) during the previous 24 hours?"
A reduction of at least 4 points in pruritus NRS from baseline is a clinically meaningful change.1
EASI, Eczema Area and Severity Index; NRS, numerical rating scale.